NEVE ILAN, Israel, Oct. 02, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced it will host an Investor Day at the Nasdaq in New York City on Tuesday, October 17, 2023. The event will include presentations and Q&A with leaders from across the company.
As there is limited capacity available, only preregistered parties will be able to attend. To attend, you must pre-register for the event using this link Nanox Investor Day. Following registration, you will receive a formal invitation with event details.
About Nanox
Nanox (NASDAQ: NNOX) is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. Nanox’s vision is to increase access, reduce costs and enhance the efficiency of routine medical imaging technology and processes, in order to improve early detection and treatment, which Nanox believes is key to helping people achieve better health outcomes, and, ultimately, to save lives. The Nanox ecosystem includes Nanox.ARC - a multi-source Digital Tomosynthesis system that is cost-effective, and user-friendly; an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic disease, (Nanox.AI); a cloud-based infrastructure (Nanox.CLOUD); and a proprietary decentralized marketplace, through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts; and a comprehensive teleradiology services platform (Nanox.MARKETPLACE). Together, Nanox’s products and services create a worldwide, innovative, and comprehensive solution that connects medical imaging solutions, from scan to diagnosis. For more information, please visit www.nanox.vision.
CONTACTS:
Media Contact:
Rachael Roselli
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Mike Cavanaugh
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$5.85 |
Daily Change: | -0.18 -2.99 |
Daily Volume: | 1,035,801 |
Market Cap: | US$342.220M |
August 20, 2024 June 05, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB